Skip to main content
Premium Trial:

Request an Annual Quote

ScienceWerke, SciGene, KFB, Genomatix, Beckman Coulter

Premium

ScienceWerke Will Distribute SciGene Products in Singapore, Malaysia

SciGene said this week that it has signed a distribution agreement with ScienceWerke, and that ScienceWerke now has exclusive rights to market and support products manufactured by SciGene in Singapore and Malaysia.

According to SciGene, ScienceWerke's SciGene portfolio will include its Hybex Microarray Incubation System and its Little Dipper Microarray Processor, as well as its BriteSpot Microarray Workstation.

Financial details were not discussed.


KFB adds Genomatix Chip Analysis Pipeline to Service

The Center of Excellence for Fluorescent Bioanalysis, or KFB, an authorized Affymetrix service provider, has signed an agreement with Genomatix Software that will enable KFB to offer Genomatix's GeneChip Analysis-Pipeline to KFB's industrial and academic customers, Genomatix said last week.

KFB customers will now receive results for their microarray experiments based on both KFB's and Genomatix's technology. In addition, they will have temporary access to Genomatix's BiblioSphere PathwayEdition, a database and analysis system, as well as data processed with Genomatix's ChipInspector data analysis tool.

Financial details were not discussed.


Beckman Coulter's Q4 Revenues Fall 5.4 Percent

Beckman Coulter reported last week that its fourth-quarter sales fell by 5.4 percent to $655.5 million from $693 million during the year-ago period. Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth.

Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.

Beckman reaffirmed its outlook for 2006 that was stated on Nov. 2, 2005, when the company released its third-quarter earnings report. Assuming stable currency, sales should be in the range of $2.53 billion to $2.60 billion, the company said.

For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.

Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.

As of Dec. 31, 2005, Beckman had $57.6 million in cash and cash equivalents.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.